Trial Profile
A Double Blind, Randomized, Active-controlled, Phase 3 Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jul 2020
Price :
$35
*
At a glance
- Drugs Tegoprazan (Primary) ; Esomeprazole
- Indications Erosive oesophagitis
- Focus Therapeutic Use
- Sponsors CJ HealthCare; HK inno.N
- 06 Mar 2019 Primary endpoint (Cumulative healing rate of erosive esophagitis at 8-week) has been met, published in the Alimentary Pharmacology and Therapeutics
- 06 Mar 2019 Results published in the Alimentary Pharmacology and Therapeutics
- 11 Sep 2017 Status changed from recruiting to completed.